

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038

Status	RECRUITING
Phase	Phase 2
Sponsor	Genentech, Inc.
Enrollment	162 participants

Key Eligibility Criteria

Inclusion (4)

- Confirmed evidence of atherosclerosis
- Left or right carotid TBR \leq 1.8 or aorta TBR \leq 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan
- Stable treatment of atherosclerosis through the use of SOC medications or revascularization
- QT interval corrected through use of Fridericia's formula (QTcF) of \leq 450 milliseconds (ms) in men and \leq 470 ms in women by a single 12-lead electrocardiogram (ECG) recording

Exclusion (11)

- Individuals with Class III and IV heart failure
 - Uncontrolled cardiac arrhythmia
 - Uncontrolled hypertension
 - Suspected or known immunocompromised state
 - Planned procedure or surgery during the study and any major surgery within 90 days prior to screening Visit 1
- ... and 6 more (see full listing online)

Locations (1 total)

Alliance Clinical West Hills (Focus Clinical Research), West Hills, California, United States